ADGRL4 and ovarian cancer: In human patients with colorectal and ovarian cancer who go on to receive systemic anti-cancer therapy, high tumour-associated endothelial ADGRL4/ELTD1 expression correlates with improved overall survival in a range of tumour types (head and neck squamous carcinoma, renal, colorectal, ovarian, and hepatocellular cancers) [1,8].